Provide comprehensive marketing strategy and tactical expertise to key clients (Medvacon Life Sciences 12/2020 to present, DRG (Decision Resources Group 2020), and Harborside Nexus (2019). Medvacon project involves development of marketing/communications strategy and plan for technical life science firm. DRG project involved pre-launch strategic and tactical plans for US Client Dynavax in preparation of HepB vaccine launch in EU. Harborside project involved detailed plan for NPs/PAs.

Global leader responsible for launch of Menactra in 70+ global markets exceeding sales of $700M. Leader of marketing team based in both France & U.S. Simultaneously tasked with upstream new product dev for a novel vaccine to convert existing doses to newer product with improved TPP. Led team efforts with brand positioning, messaging, sales training, medical ed, public policy efforts, etc. Responsible for anti-infective strat plan. Aligned w pricing/access teams on U.S./global distribution

US team leader for large marketing effort with company's largest $5.5B franchise. Led cross functional and joint venture teams to facilitate decision making and timely strategic and tactical plans. Launched new product indication in hospital setting for STEMI (ST elevated MI) with strong market expansion and competitive defense plans. Key decision maker on institutional, health system, and managed care pricing/contracting strategy for 2nd largest Rx brand in world behind Lipitor.

US marketer responsible for health care professional, consumer, and payor strategies and POA implementation for large specialty therapeutic areas including neuroscience and ophthalmology. Developed novel early stage diagnostic and screening tools leading to massive growth post launch.

National product manager for anti-infectives franchise launching Lamisil tablets as Novartis first blockbuster brand. Responsible for all HCP, Institutional and consumer strategy/tactics. Worked in parallel with acct mgt team on contracting strategy for hospitals, health systems, HMOs, etc and developed Health Economic model to justify higher pricing position.